Placeholder Banner

Congressman Tom Suozzi to Spotlight Scientific and Economic Development Advancements in New York

July 27, 2018

Congressman Tom Suozzi will join leaders of New York’s biotechnology community for a tour of Alexandria LaunchLabs.

The group will discuss prospects for, and impediments to, the continued growth of this important New York industry.1 The Congressman also will discuss how federal biotech policy and budget debates could impact biomedical innovation.

WHAT:           

Tour and Q&A at Alexandria LaunchLabs

WHO:             

Congressman Tom Suozzi

Ron Cohen, CEO, Acorda Therapeutics

Jim Greenwood, ​President & CEO, BIO

Jennifer Bland,​ CEO, NewYorkBIO

Other members of the New York bioscience community 

 

WHEN:

Monday, July 30, 2018 at 11:00 am

 

WHERE:          

Alexandria LaunchLabs

430 East 29th Street

14th Floor

New York City, NY

 

Media requested to RSVP to George Goodno, [email protected]
 

1 https://www.bio.org/sites/default/files/NY-BIO2018%20-%20state%20profile.pdf

 

 

About Alexandria LaunchLabs

Alexandria LaunchLabs is the premier, full-service startup platform designed to dramatically accelerate the growth of early-stage life science startups. With its flagship site at the Alexandria Center® for Life Science – New York City and its Cambridge site at the Alexandria Center® at One Kendall Square, Alexandria LaunchLabs provides move-in ready office/laboratory space, first-class support resources, shared equipment and services, creative amenities and access to startup capital through the Alexandria Seed Capital Platform— all of which are critical for driving the growth of seed- and early-stage companies across the country. The Alexandria LaunchLabs team is currently accepting applications for future members in New York City and Cambridge. For more information or to apply, please visit www.alexandrialaunchlabs.com.

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…